<DOC>
	<DOCNO>NCT00937625</DOCNO>
	<brief_summary>The aim study investigate toxicity clinical response therapy tumor infiltrate lymphocyte treatment advance melanoma . Patient receive single treatment consist condition chemotherapy seven day ( cyclophosphamide two day fludarabine five day ) , intravenous infusion high number vitro expand tumor infiltrate lymphocyte follow two week daily low-dose interleukine-2 . Patients evaluated toxicity , tumor response , immune response . After first 6 patient treatment IL-2 change include high dos IL-2 ( see intervention )</brief_summary>
	<brief_title>T-cell Based Immunotherapy Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients histological proven skin derive progressive metastatic locally advanced malignant melanoma . Further inclusion criterion : Performance Status 0 1 , surgical available metastasis , least one measurable lesion , acceptable CBC blood chemistry result . Acceptable organ function . Patients history malignancy less five year ago . Brain metastasis . Other significant illness include severe allergy , asthma , DM , angina pectoris , congestive heart failure , chronic infection , active autoimmune disease . Treatment immune suppressive drug , experimental drug , antineoplastic drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>